NPI: 1235157280 · BILLINGS, MT 59101 · Clinical Medical Laboratory · NPI assigned 07/18/2006
| Authorized Official | CARTIER, GERALD (VP NATIONAL BILLING) |
| Parent Organization | QUEST DIAGNOSTICS INCORPORATED |
| NPI Enumeration Date | 07/18/2006 |
Other providers sharing the same authorized official: CARTIER, GERALD
| Provider | City | State | Total Paid |
|---|---|---|---|
| QUEST DIAGNOSTICS LLC IL | NEW BRIGHTON | MN | $6.55M |
| UNILAB CORPORATION | BANNING | CA | $37K |
| METWEST INC. | WEST VALLEY CITY | UT | $11K |
| QUEST DIAGNOSTICS CLINICAL LABORATORIES INC | ROCKY MOUNT | NC | $7K |
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 7,189 | $69K |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 84443 | Thyroid stimulating hormone (TSH) | 1,021 | 994 | $21K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1,448 | 1,372 | $17K |
| 80061 | Lipid panel | 915 | 887 | $11K |
| 80053 | Comprehensive metabolic panel | 1,455 | 1,409 | $9K |
| 83036 | Hemoglobin; glycosylated (A1C) | 390 | 379 | $4K |
| 84439 | 192 | 188 | $2K | |
| 80048 | Basic metabolic panel (calcium, ionized) | 230 | 211 | $1K |
| 84153 | 67 | 64 | $1K | |
| 82728 | 58 | 58 | $721.55 | |
| 82040 | 90 | 88 | $599.30 | |
| 83550 | 59 | 59 | $491.05 | |
| 83540 | 62 | 62 | $378.98 | |
| 85652 | 171 | 168 | $331.09 | |
| 84702 | 14 | 12 | $250.76 | |
| 84550 | 59 | 59 | $237.02 | |
| 85610 | 63 | 60 | $232.39 | |
| 83735 | 38 | 36 | $203.74 | |
| 81003 | 65 | 64 | $142.05 | |
| 85027 | 13 | 12 | $69.66 | |
| 84450 | 96 | 93 | $18.60 | |
| 84520 | 91 | 89 | $6.25 | |
| 84460 | 95 | 92 | $0.00 | |
| 82565 | 90 | 88 | $0.00 | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 26 | 25 | $0.00 |
| 36415 | Collection of venous blood by venipuncture | 369 | 350 | $0.00 |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 12 | 12 | $0.00 |